Committee for Medicinal Products for Human Use (CHMP) has recommended approval of MSD’s KEYTRUDA for two gynaecological ...

The approval for the KEYTRUDA regimen is supported by results from the Phase II/III IND.227/KEYNOTE-483 trial.

PDS Biotechnology's HPV-directed immunotherapy is sparking optimism in the biotech industry. Click here to find out why I am ...

Folks with "high-risk" bladder cancers -- tumors that had already invaded nearby muscle -- doubled the time they were ...

In H1 2024, promising randomized Phase I data on TG4050 were presented at AACR 2024 (see poster here). These data provide a robust ... shrinkage in 2 of 6 injected lesions.In combination with ...

Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024 In patients with any PD-L1 ...

Danish clinical-stage techbio firm Evaxion Biotech,which is developing AI-Immunology powered vaccines, announced new clinical ...

PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the ...

Pfizer Inc. (NYSE: PFE) continues to showcase potential practice-changing research and next-generation candidates across its robust Oncology portfolio at the European Society for Medical Oncology ...

Three partial responses (PR) and one stable disease (SD) out of four evaluable patients with Cutaneous T-cell Lymphoma (CTCL) ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), ...

Eight abstracts, including two oral presentations, feature new clinical data from Astellas' oncology portfolio and two lead pipeline programs ac ...